Navigation Links
New Subanalyses of the RE-LY Trial Showed Pradaxa Reduced Stroke Risk in Patients With Varying CHA2DS2-VASc Scores and Types of Non-Valvular Atrial Fibrillation
Date:4/4/2011

RIDGEFIELD, Conn., April 4, 2011 /PRNewswire/ -- Two new retrospective subanalyses of the RE-LY® trial, involving Pradaxa® (dabigatran etexilate mesylate) capsules, suggested that the reduction in stroke risk achieved with PRADAXA 150mg over warfarin (1) occurred irrespective of CHA2DS2-VASc risk score (2) and the type of non-valvular atrial fibrillation (NVAF) (permanent, persistent and paroxysmal)(3).  The results were presented at the American College of Cardiology's 60th Annual Scientific Session. (2,3)  

The first subanalysis assessed the impact of the novel CHA2DS2-VASc risk score,(2) which determines stroke risk based on age, sex and the presence of comorbidities,(4) on outcomes in the RE-LY trial.  Patients were grouped into quartiles based on CHA2DS2-VASc score (0-2, 3, 4, 5-9) (2) and results showed that PRADAXA 150mg was associated with reductions in stroke risk compared to warfarin for all four quartiles (0-2, RR = 0.63; 3, RR = 0.61; 4, RR = 0.53; 5-9, RR = 0.77; interaction p-value = 0.60).(2) Results of the analysis showed there was a significant interaction between CHA2DS2-VASc score and rates of major bleeding, with lower rates for PRADAXA 150mg compared to warfarin for patients in the first three quartiles, but an increased rate of major bleeding for the quartile at greatest risk (0-2, RR = 0.75; 3, RR = 0.74; 4, RR = 0.83; 5-9, RR = 1.33; interaction p-value = 0.003).(2)

"This analysis suggests that PRADAXA 150mg taken twice daily may reduce the risk of stroke compared to warfarin across the levels of NVAF-associated stroke risk, as determined by the CHA2DS2-VASc score," said Paul Reilly, Ph.D., clinical program director, Boehringer Ingelheim Pharmaceuticals, Inc.  "These findings are important because the risk of stroke in patients with NVAF increases significantly with the presence of comorbidities, such as diabetes or hypertension."

PRADAXA was also evaluated in a second RE-LY suban
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. New Sub-Analysis of RE-LY Trial Examines Pradaxa in Patients with Atrial Fibrillation Undergoing Cardioversion
2. New Analyses of Data From RE-LY Trial, Involving Oral Anticoagulant Pradaxa, to be Presented at American Heart Associations Scientific Sessions
3. Data Published in The Lancet Compare Dabigatran Etexilate to Dose-Adjusted Warfarin Across RE-LY® Trial Centers
4. Boehringer Ingelheim Announces Enrollment is Complete for the Largest Atrial Fibrillation Outcomes Trial - The RE-LY(TM) Study
5. Publication in SLEEP Journal Demonstrates Positive Results of Large Multi-Center Clinical Trial for Provent® Sleep Apnea Therapy
6. Regado Biosciences, Inc. Presents Results of the RADAR Phase 2b Clinical Trial of its REG1 Anticoagulation System
7. Boston Scientific ION™ Platinum Chromium Stent System Demonstrates Strong Performance in Analysis of PERSEUS and TAXUS ATLAS Clinical Trial Data
8. Analysis of Data Across Multiple Drug Eluting Stent Trials Reinforces Positive Clinical Performance of XIENCE V®
9. REMEDIAL II Results on PLC Systems RenalGuard® to be Presented at ACC 2011s Late Breaking Clinical Trial Session
10. Omeros Reports Outcome of Phase 3 Trials of OMS103HP
11. Conatus Pharmaceuticals Presents Results From a Phase 2 Clinical Trial of CTS-1027 in HCV Genotype 1 Null-Responders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... YORK , Jan. 23, 2015 /PRNewswire/-- Harwood Feffer LLP ... board of directors of Advaxis, Inc. ("Advaxis" or the ... board has breached its fiduciary duties to shareholders. ... on an investing website reporting that Advaxis had misrepresented ...
(Date:1/23/2015)... Idaho , Jan. 23, 2015  Now available for ... No. 7,849,611) support that prevents ankle sprains by cushioning ... brace, it fits securely around the outside of any ... mobility & comfort while still offering protection against sprains. ...
(Date:1/23/2015)... , Jan. 23, 2015 Cord Blood America, Inc. ... ("CBAI" or the "Company")  filed a Preliminary Proxy Statement, Schedule ... ) today, and provides an update for shareholders detailing why ... is requested. Dear Shareholders, As we ...
Breaking Medicine Technology:Harwood Feffer LLP Announces Investigation of Advaxis, Inc. 2The Armor1 Ankle Roll Guard is the New Breakthrough Solution for Ankle Sprain Prevention! 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 3Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 4
... Approval of New Anti-TNF Therapy in Three Rheumatic Diseases ... and KENILWORTH, N.J., June 26 Centocor Ortho Biotech ... announced today that the Committee for Medicinal Products for ... adopted a positive opinion recommending the approval of SIMPONI(TM) ...
... As of mid-2009, The Michael J. Fox Foundation for ... high-risk, high-reward approaches to Parkinson,s therapeutic development through its ... investigations of the safety and efficacy of an FDA-approved ... a tenuous link between PD and certain strains of ...
Cached Medicine Technology:SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 2SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 3SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 4SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 5SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 6SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 7SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 8SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 9SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 10MJFF's Rapid Response Innovation Awards Hit Mid-2009 With Over $1 Million Funded in High-Risk/High-Reward Approaches to Parkinson's Disease 2MJFF's Rapid Response Innovation Awards Hit Mid-2009 With Over $1 Million Funded in High-Risk/High-Reward Approaches to Parkinson's Disease 3
(Date:1/22/2015)... its top dressmaking technologies, has been a leading dress supplier ... latest designs of wedding dresses and launching a site-wide promotion ... the fresh new products are designed for 2015, and they ... All the clothes from LunaDress follow up with the latest ...
(Date:1/22/2015)... Glendale, AZ (PRWEB) January 22, 2015 Padre ... a long supporter of Pro Player Health Alliance ... with Padre Murphy's in getting everyone, including NFL greats, treated ... one of the leading groups supporting the cause in the ...
(Date:1/22/2015)... Blue Cross and Blue Shield of Minnesota ... it means to “Live Fearless.” , The “Faces ... their stories about how they or someone they know has ... living in the moment. By telling these types of stories ...
(Date:1/22/2015)... Dallas, TX (PRWEB) January 22, 2015 ... the issue of experience and person-centeredness in the long-term ... moving towards action across the continuum. The paper, “The ... the Continuum,” engages perspectives and practices of the patient, ...
(Date:1/22/2015)... Carinsurancesavings.biz has released a new blog post presenting the basic ... , Purchasing an accidental death and dismemberment rider for a ... rider provides benefits if the insured dies in an accident. ... of life insurance. , AD&D is not expensive and ...
Breaking Medicine News(10 mins):Health News:LunaDress Shows The Latest Styles Of Wedding Dresses In 2015 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 3Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2
... The American people,through the United States ... of four partners, will assist in building ... prevention, malaria and child,survival programs. The Behavior ... district stakeholders, the private sector and Government ...
... The incidence of,type 2 diabetes is rising, especially ... and obesity abound. In addition to weight and,inactivity, ... developing type 2,diabetes. The incidence of diabetes is ... prevalence. An estimated 32 million Asian,Indians have been ...
... KANSAS CITY, Mo., Feb. 29 Hostess(R) 100 ... New Product Launch (MMNPL) of 2007 in,a survey ... Resources, Inc. (IRI). Hostess 100 Calorie Pack Cup ... portion-,controlled, snack sized packages each containing three scrumptious ...
... of the Indian spice turmeric for psoriasis received a ... a leading dermatology journal stating that the low response ... the exotic spice was probably a result of the ... of Medicine found that despite strong scientific evidence in ...
... 29 Richard P. Miller,of Marlton, president and CEO ... of the board of the New Jersey Hospital Association,(NJHA,) ... as the appointment of new board members, was held,during ... "As we look to the future of New ...
... Health Corp. (Nasdaq:,WBMD) and HLTH Corporation (Nasdaq: HLTH ... participate at the Morgan Stanley Technology,Conference on Tuesday, March ... and the general public are invited to listen to ... The broadcast,can be accessed at http://www.wbmd.com (in ...
Cached Medicine News:Health News:USAID Implements Behavior Change and Social Marketing Program in Rwanda 2Health News:Mayo Researchers Look for Explanation Behind High Incidence of Diabetes Among Asian Indians 2Health News:Mayo Researchers Look for Explanation Behind High Incidence of Diabetes Among Asian Indians 3Health News:Hostess(R) 100 Calorie Pack Cup Cakes Named A Most Memorable New Product of 2007 2Health News:Popular alternative therapy for psoriasis performs no better than placebo 2Health News:New Jersey Hospital Association Names New Chairman, Appoints Board Officers and New Members 2
Rubber bronchial catheter with thumb valve, one eye, coude whistle tip, with pop-up solution container, two vinyl gloves in peel-open package....
Gentle-Flo® Standard Connector., ,Indications For Usage: ,Removal of secretions from respiratory tract....
Sterile Straight Packed TOUCH-TROL Suction Catheters...
Sterile Straight Packed TOUCH-TROL Suction Catheters...
Medicine Products: